Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2017

View Archived Issues

Aclaris Therapeutics acquires Confluence Life Sciences

FDA grants OCU-300 orphan drug designation for the treatment of ocular graft-versus-host disease

Otsuka updates pipeline progress of second quarter 2017

AMPK as a novel therapeutic target for Niemann-Pick disease, type C

Novel ZIKV antibody-based assay demonstrates high sensitivity and specificity

Promising phase III data for icotinib in NSCLC brain metastases

RXi Pharmaceuticals begins preclinical development for RXI-762 and RXI-804

DEL MAR Stage 2 study of Luminate in DME meets primary endpoint

Mologen announces results from extension phase of TEACH study of lefitolimod in HIV

PharmaMar begins study of quadruple combination with Aplidin in multiple myeloma

FDA grants orphan drug designation to cobitolimod in ulcerative colitis

2X Oncology validates Drug Response Predictor for 2X-121

Pew to launch new digital SPARK platform to aid in antibiotic discovery

Cempra and Melinta Therapeutics announce plans to merge

Lipocine resubmits LPCN-1021 NDA

Nippon Chemiphar, Kinki University describe novel calcium channel subunit alpha Cav3.2 blockers

Immuron cleared to begin phase I study of IMM-529

Taipei Medical University identifies new niclosamide prodrugs

Tissue Regenix announces the acquisition of CellRight Technologies

American Gene Technologies International presents farnesyl diphosphate synthase inhibitors

Launch of Prevail Therapeutics, new company focused on therapies for Parkinson's

FDA grants orphan drug designation for blisibimod as treatment of IgA nephropathy

Servier, Vernalis divulge novel Mcl-1 inhibitors

Merck & Co. patents anti-coagulation factor XI antibodies

Editas Medicine achieves second milestone under Juno Therapeutics collaboration

Galapagos presents phase II results from FLORA study of GLPG-1690

Shanghai Institute Materia Medica, Sunnylife Pharma disclose BTK inhibitors

EndoLogic reports outcome of pre-IND meeting on phase II study of renzapride

GENETIC-AF phase IIb trial of Gencaro recommended for completion

Heron Therapeutics announces successful end-of-phase II meeting with FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...